Editorial: Drug-resistant Mycobacterium tuberculosis

Helena I M Boshoff; Digby F Warner; Ben Gold

doi:10.3389/fcimb.2023.1215294

Editorial: Drug-resistant Mycobacterium tuberculosis

Front Cell Infect Microbiol. 2023 May 19:13:1215294. doi: 10.3389/fcimb.2023.1215294. eCollection 2023.

Authors

Helena I M Boshoff¹, Digby F Warner^{2

3}, Ben Gold⁴

Affiliations

¹ Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, MD, United States.
² Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
³ Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
⁴ Department of Microbiology & Immunology, Weill Cornell Medicine, New York, NY, United States.

No abstract available

Keywords: Mycobacterium tuberculosis; antimicrobial resistance (AMR); drug discovery; drug resistance; drug synergy; drug tolerance; phenotypic resistance; tuberculosis.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural

MeSH terms

Antitubercular Agents / pharmacology
Antitubercular Agents / therapeutic use
Humans
Mycobacterium tuberculosis* / genetics
Tuberculosis, Multidrug-Resistant* / drug therapy
Tuberculosis, Multidrug-Resistant* / microbiology

Substances

Antitubercular Agents

Grants and funding

R21 AI159572/AI/NIAID NIH HHS/United States